Similar articles for PMID: 23117188

Year	Number of Results
2005	1
2007	3
2009	2
2010	12
2011	14
2012	8
2013	15
2014	13
2015	13
2016	13
2017	10
2018	14
2019	5
2020	12
2021	23
2022	20
2023	8
2024	0

1

Efficacy of roflumilast in the COPD frequent exacerbator phenotype.

Wedzicha JA, Rabe KF, Martinez FJ, Bredenbröker D, Brose M, Goehring UM, Calverley PMA. Wedzicha JA, et al. Chest. 2013 May;143(5):1302-1311. doi: 10.1378/chest.12-1489. Chest. 2013. PMID: 23117188 Clinical Trial.

2

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF. Calverley PM, et al. Int J Chron Obstruct Pulmon Dis. 2012;7:375-82. doi: 10.2147/COPD.S31100. Epub 2012 Jun 20. Int J Chron Obstruct Pulmon Dis. 2012. PMID: 22791991 Free PMC article. Clinical Trial.

3

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Martinez FJ, et al. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684586 Clinical Trial.

4

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Rennard SI, et al. Respir Res. 2011 Jan 27;12(1):18. doi: 10.1186/1465-9921-12-18. Respir Res. 2011. PMID: 21272339 Free PMC article.

5

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Calverley PM, et al. Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Lancet. 2009. PMID: 19716960 Clinical Trial.

6

Roflumilast: doubtful efficacy but clear harms in COPD.

[No authors listed] [No authors listed] Prescrire Int. 2013 Jan;22(134):5-9. Prescrire Int. 2013. PMID: 23367674

7

Roflumilast in the management of chronic obstructive pulmonary disease.

Lipari M, Benipal H, Kale-Pradhan P. Lipari M, et al. Am J Health Syst Pharm. 2013 Dec 1;70(23):2087-95. doi: 10.2146/ajhp130114. Am J Health Syst Pharm. 2013. PMID: 24249758 Review.

8

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Rabe KF. Rabe KF. Br J Pharmacol. 2011 May;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x. Br J Pharmacol. 2011. PMID: 21232047 Free PMC article. Review.

9

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI. Martinez FJ, et al. Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC. Am J Respir Crit Care Med. 2016. PMID: 27585384 Clinical Trial.

10

Clinical Considerations for Roflumilast: A New Treatment for COPD.

Kelly Freeman ML. Kelly Freeman ML. Consult Pharm. 2012 Mar;27(3):189-93. doi: 10.4140/TCP.n.2012.189. Consult Pharm. 2012. PMID: 22421519

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

162 results

Results by year